We are live on ! Find out more
SGYP

Synergy Pharmaceuticals, Inc Common Stock
SGYP

Delisted

SGYP was delisted on the 7th of March, 2019.

128 hedge funds and large institutions have $175M invested in Synergy Pharmaceuticals, Inc Common Stock in 2016 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 41 increasing their positions, 33 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

238% more call options, than puts

Call options by funds: $4.95M | Put options by funds: $1.46M

24% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 33

4% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 23

1% more funds holding

Funds holding: 127128 (+1)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

51% less capital invested

Capital invested by funds: $360M → $175M (-$185M)

Holders
128
Holders Change
+1
Holders Change %
+0.79%
% of All Funds
3.41%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
24
Increased
41
Reduced
33
Closed
23
Calls
$4.95M
Puts
$1.46M
Net Calls
+$3.48M
Net Calls Change
+$1.29M
Name Holding Trade Value Shares
Change
Change in
Stake
UBS Group
51
UBS Group
Switzerland
$321K -$708K -195,631 -63%
Creative Planning
52
Creative Planning
Kansas
$320K +$400K +110,486 +2,009%
SKK
53
Shepherd Kaplan Krochuk
Massachusetts
$319K +$419K +115,670 New
Simplex Trading
54
Simplex Trading
Illinois
$270K +$274K +75,700 +340%
New York State Common Retirement Fund
55
New York State Common Retirement Fund
New York
$269K -$108K -29,747 -23%
RhumbLine Advisers
56
RhumbLine Advisers
Massachusetts
$268K +$4.67K +1,290 +1%
ProShare Advisors
57
ProShare Advisors
Maryland
$266K -$34.7K -9,576 -9%
TI
58
Telemetry Investments
New York
$263K +$141K +38,900 +69%
CD
59
Carl Domino
Florida
$246K +$90.5K +25,000 +39%
Wells Fargo
60
Wells Fargo
California
$232K -$29.1K -8,033 -9%
MLICM
61
Metropolitan Life Insurance Company (MetLife)
New York
$219K
Balyasny Asset Management
62
Balyasny Asset Management
Illinois
$206K -$129K -35,730 -32%
Manulife (Manufacturers Life Insurance)
63
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$189K +$10.8K +2,984 +4%
NFA
64
Nationwide Fund Advisors
Ohio
$175K -$10.2K -2,825 -4%
AFIA
65
America First Investment Advisors
Nebraska
$174K +$228K +62,947 New
DekaBank Deutsche Girozentrale
66
DekaBank Deutsche Girozentrale
Germany
$173K +$23.5K +6,500 +11%
AIG
67
American International Group
New York
$162K
TAM
68
Tocqueville Asset Management
New York
$152K
AQR Capital Management
69
AQR Capital Management
Connecticut
$150K -$81.8K -22,590 -29%
T. Rowe Price Associates
70
T. Rowe Price Associates
Maryland
$142K +$57.6K +15,900 +45%
Tudor Investment Corp
71
Tudor Investment Corp
Connecticut
$133K +$94.5K +26,087 +118%
VOYA Investment Management
72
VOYA Investment Management
Georgia
$126K
BA
73
BlackRock Advisors
Delaware
$124K +$11.3K +3,122 +7%
UBS AM
74
UBS AM
Illinois
$123K -$19.2K -5,300 -11%
VEA
75
Virtus ETF Advisers
New York
$120K -$9.79K -2,702 -6%

SGYP Hedge Fund Activity: Q1 2016 in Review

128 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Synergy Pharmaceuticals, Inc Common Stock (SGYP) for Q1 2016, worth a combined $175M — down 51% from $360M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new SGYP positions and 23 closed out — a net gain of 1 holder — while 41 added to existing stakes and 33 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $7.97M. The largest seller was Citadel Advisors, cutting an estimated $7.03M.

  • 128 institutional investors held Synergy Pharmaceuticals, Inc Common Stock (SGYP) as of Q1 2016, up from 127 in Q4 2015.
  • Funds reported $175M of Synergy Pharmaceuticals, Inc Common Stock stock for Q1 2016, down 51% quarter-over-quarter.
  • 24 funds opened new Synergy Pharmaceuticals, Inc Common Stock positions in Q1 2016 and 23 closed out, a net change of +1 holder.
  • The largest Synergy Pharmaceuticals, Inc Common Stock buyer in Q1 2016 was Armistice Capital, an estimated $7.97M added.
  • The largest Synergy Pharmaceuticals, Inc Common Stock seller in Q1 2016 was Citadel Advisors, an estimated $7.03M sold.

Based on aggregated 13F filings for Q1 2016.